HTA162 German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit
Abstract
Authors
Jörg Tomeczkowski Paul Bussilliat Kirsten Heike Herrmann Tanja Heidbrede Ulrike Osowski Friedhelm Leverkus Charalabos-Markos Dintsios